Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

6,747 total articles

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences, a clinical-stage biotech company specializing in precision therapies for solid tumors, announced that its senior management will participate in two major investor conferences in May 2026 to discuss the company's developments and outlook. Live webcasts will be available and archived on the company's investor relations website.

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317

Molecular Partners reports progress in its lead Radio-DARPin MP0712 with a Phase 1/2a study underway in multiple US clinical sites and initial data expected in 2026. The company unveiled an isotope-agnostic Radio-DARPin strategy enabling flexible therapeutic payloads and strengthened its financial position with CHF 79 million cash, supporting pipel…

Correction: South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

Correction: South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

South Jersey Industries, Inc. announced a cash tender offer to repurchase all outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 at $920 per $1,000 principal amount plus accrued interest. The offer aims to refinance debt subject to market and legal conditions, with no minimum tender amount required. The tender will expi…

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. Highlights FDA Filing of VLN® MRTP Renewal Applications for Scientific Review

22nd Century Group, Inc. announced that the FDA has accepted for scientific review the company's renewal applications for their VLN® King and VLN® Menthol King cigarettes, the first combusted cigarettes authorized as Modified Risk Tobacco Products (MRTP). These renewals, if approved, will allow continued marketing of these reduced nicotine cigarett…

SEGG Media and Sports.com Kickoff Headline Sponsorship with Soccerex as Global Football Industry Convenes in Amsterdam

SEGG Media and Sports.com Kickoff Headline Sponsorship with Soccerex as Global Football Industry Convenes in Amsterdam

SEGG Media, a Nasdaq-listed sports and entertainment company, announced its expanded partnership with Soccerex by becoming the official headline sponsor for all 2026 and 2027 Soccerex events. The company is actively participating in Soccerex Europe 2026 in Amsterdam, engaging with key football stakeholders to grow its sports media and fan engagemen…

South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

South Jersey Industries, Inc. Commences Tender Offer to Purchase for Cash Any and All of the Outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031

South Jersey Industries, Inc. has announced a cash tender offer to repurchase any and all of its outstanding 2018 Series A 3.70% Remarketable Junior Subordinated Notes due 2031 at $92 per $1,000 principal amount plus accrued interest. The offer expires on May 26, 2026, with settlement on May 29, 2026. Completion of the tender is contingent upon cer…

Kyivstar Shareholders Re-elect Board and Chairman, Demonstrating Shareholder Confidence in Leadership

Kyivstar Shareholders Re-elect Board and Chairman, Demonstrating Shareholder Confidence in Leadership

Kyivstar Group Ltd., Ukraine's leading digital operator listed on Nasdaq, held its 2026 Annual General Meeting where shareholders re-elected the current board and Chairman Kaan Terzioğlu, demonstrating continued confidence in the company's strategic direction. Kyivstar reported strong 2025 financial results with a 25.9% increase in revenue to USD 1…

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Announces $3 Million Private Investment at $8 Per Share, a 14% Premium from Latest Market Close

Tevogen Bio Holdings Inc. announced a private investment in public equity (PIPE) financing of $3 million at $8 per prefunded warrant, representing a 14% premium over the previous closing price. The financing, backed by existing investor The Patel Family, LLP, aims to support ongoing operations, strategic growth, and general corporate purposes. The …

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition

Syndax Pharmaceuticals highlighted 12 abstracts featuring their FDA-approved menin inhibitor Revuforj (revumenib) accepted for presentation at the European Hematology Association (EHA) 2026 Congress. The data demonstrate strong activity across various subtypes of acute leukemia, favorable tolerability, promising post-transplant maintenance outcomes…

Plains All American Pipeline and Plains GP Holdings Announce Completion of Canadian NGL Divestiture

Plains All American Pipeline and Plains GP Holdings Announce Completion of Canadian NGL Divestiture

Plains All American Pipeline and Plains GP Holdings finalized the sale of Plains Midstream Canada, their natural gas liquids (NGL) business, to Keyera Corp for net proceeds of approximately $3.3 billion. The transaction supports debt reduction and strategic focus on crude oil midstream operations with more stable cash flows and reduced volatility. …

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL To Report First Quarter 2026 Financial Results on May 15th

NEXGEL, a US-based healthcare and consumer products company specialized in hydrogel technologies, will report its first quarter 2026 financial results on May 15, 2026. The company will hold a conference call at 12:00 P.M. ET the same day to discuss the results. NEXGEL has a strong presence in healthcare, beauty, and OTC products and maintains strat…

Lemonade Expands Renters Insurance to Louisiana

Lemonade Expands Renters Insurance to Louisiana

Lemonade, a tech-driven insurance company listed on NYSE as LMND, has expanded its renters insurance product to Louisiana. The service offers customizable coverage through a mobile app at prices starting around $5 monthly, significantly lower than average market rates. This move marks another step in Lemonade's nationwide growth, targeting renters …

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology and Kyowa Kirin to Present Updated Frontline Ziftomenib / 7+3 Combination Data at EHA 2026 Congress

Kura Oncology and Kyowa Kirin will present updated Phase 1 KOMET-007 trial results showing high and durable response rates of ziftomenib in combination with standard chemotherapy (7+3) in newly diagnosed acute myeloid leukemia (AML) patients with NPM1 mutations or KMT2A rearrangements. The data feature a 96% complete response rate and deep molecula…

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

First Real-World Evidence Study of RYTELO® (imetelstat) in Lower-risk Myelodysplastic Syndromes (LR-MDS) to be Presented at EHA 2026

Geron Corporation announced the presentation of the first real-world evidence study of RYTELO (imetelstat) in patients with lower-risk myelodysplastic syndromes (LR-MDS) at the EHA 2026 Congress. The study, conducted at Moffitt Cancer Center, demonstrated safety and clinical efficacy consistent with the Phase 3 IMerge trial, including in heavily tr…